In the course of studies aimed at the role of oxidative stress in the development of metastatic potential in the LNCaP-C4-2B prostate cancer progression model system, we found a relative decrease in the level of expression of the cytoplasmic nicotinamide riboside: quinone oxidoreductase (NQO2) and an increase in the oxidative stress in C4-2B cells compared to that in LNCaP or its derivatives C4 and C4-2. It was also found that C4-2B cells specifically shed large extracellular vesicles (LEVs) suggesting that these LEVs and their cargo could participate in the establishment of the osseous metastases. The level of expression of caveolin-1 increased as the system progresses from LNCaP to C4-2B. Since NQO2 RNA levels were not changed in LNCaP, C4, C4-2, and C4-2B, we tested an altered cellular distribution hypothesis of NQO2 being compartmentalized in the membrane fractions of C4-2B cells which are rich in lipid rafts and caveolae. This was confirmed when the detergent resistant membrane fractions were probed on immunoblots. Moreover, when the LEVs were analyzed for membrane associated caveolin-1 as possible cargo, we noticed that the enzyme NQO2 was also a component of the cargo along with caveolin-1 as seen in double immunofluorescence studies. Molecular modeling studies showed that a caveolin-1 accessible site is present in NQO2. Specific interaction between NQO2 and caveolin-1 was confirmed using deletion constructs of caveolin-1 fused with glutathione S-transferase (GST). Interestingly, whole cell lysate and mitochondrial preparations of LNCaP, C4, C4-2, and C4-2B showed an increasing expression of glutaminase (GLS, kidney type). The extrusion of LEVs appears to be a specific property of the bone metastatic C4-2B cells and this process could be inhibited by a GLS specific inhibitor BPTES, suggesting the critical role of a functioning glutamine metabolism. Our results indicate that a high level of expression of caveolin-1 in C4-2B cells contributes to an interaction between caveolin-1 and NQO2 and to their packaging as cargo in the shed LEVs. These results suggest an important role of membrane associated oxidoreductases in the establishment of osseous metastases in prostate cancer. 
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| INTRODUCTION
Prostate adenocarcinoma is recognized as the second leading cause of death in men in North America. 1 Although the mechanisms by which prostate cancer is driven are not yet completely understood, aspects such as age, race, family history of prostate cancer, lifestyle, and diet are factors that are under investigation. [2] [3] [4] Prostate cancer incidence is tested on the basis of the prostate-specific antigen (PSA) blood test and histological stages. 5 Early stages of prostate cancer exhibit cells that are only able to survive in an androgen-rich environment and hence they are often treated with androgen-deprivation therapies. While it is common that bony metastases are seen at first clinical diagnosis of prostate cancer in many men, there is also an increasing suspicion that the selective and stringent pressure imposed by the androgen ablation therapy on the residual prostate cancer cells might actually accelerate the development of more aggressive, metastatic, and rapidly growing prostate cancers. 6 This is particularly in part due to fact that the prostate cancer cells are adept at maintaining functional androgen receptor signaling even in an androgen-independent environment, to drive cancer growth and to acquire a metastatic advantage. 6, 7 Studies have been done to dissect the mechanisms that drive prostate cancer transition from androgen dependence to androgen independence, in animal models. 8, 9 However, the complete molecular mechanism of prostate cancer progression is yet to be elucidated, and therefore, even the best available treatment for advanced prostate cancers often result in debilitating osseous metastases, often with a fatal outcome. 10, 11 The LNCaP prostate cancer progression model, developed by Leland
Chung's laboratory, systematically recapitulates the way in which prostate cancer develops and eventually metastasizes preferentially to the skeleton. 12, 13 Thus, this model system lends itself to systematic preclinical studies to understand the stages involved in prostate cancer progression to androgen independence and the establishment of bony metastases. Characterization of the LNCaP progression model revealed an increasing "bone cell-like" differentiation from LNCaP human prostate carcinoma cells to its derivatives C4, C4-2, and C4-2B. Interestingly, LNCaP and C4 are androgen dependent whereas C4-2 and C4-2B cells are androgen independent. This in vitro model mirrors the progression of human prostate cancer in vivo. 12, 13 In addition to being androgen independent, C4-2B cells have the propensity to metastasize to the bone.
Bone is a restrictive and protective environment that is normally hostile to the growth and survival of cancer cells metastasizing from another organ.
Therefore, in order for prostate cancer cells to metastasize in the bone, they mimic the properties of osteoblasts and osteoclasts, which bone cells are made of in order to survive, a phenomenon known as "osteomimicry."
The classic "seed and soil" theory states that the soil, the bone microenvironment, determines the selectivity of the seed, in this case the prostate cancer metastatic cell line C4-2B. 14, 15 Therefore, in order for the seed to take root, the prostate cancer cells closely mimic the fertile soil of the local bony microenvironment by exhibiting osteomimicry.
Several epidemiological studies indicate that while the rate of occurrence of clinically indolent prostate cancer is similar worldwide, the rate of occurrence of clinically significant and metastatic prostate cancer is markedly lower in Asia than in Western populations. 16 It has been proposed that these differences could be due, a large part, to the influencing factors such as diet and other nutritional factors rather than genetic variations because Asian men who adopt a Western life style
show an increasing incidence of clinically significant disease. 17 Apart from Asian men, incidence of prostate cancer among men is also significantly low in France which is due, a significant part, to a large intake of red wine, a natural source of resveratrol, leading to the concept of "French Paradox." 18, 19 Work from our laboratories have focused for many years on the molecular mechanisms of androgen independence and bone metastasis in prostate cancer, with particular reference to the use of curcumin (used in Asian cuisine) and resveratrol (found in red wine) as significant anti-inflammatory, anti-oxidative agents, and as nutritional modulators of cancer progression. [20] [21] [22] [23] [24] Our earlier work on the mechanisms of androgen independence in prostate cancer cells has led to a better understanding of the function of the enzyme NRH:
quinone oxidoreductase (NQO2) in prostate carcinogenesis. 25, 26 In this communication, the role of the enzyme NQO2 is investigated further with respect to its role not only in regulating oxidative stress but also in regulating prostate cancer metastasis and how glutamine metabolism influences all these processes. Our results highly suggest a heretofore uninvestigated role for the enzyme NQO2 in the genesis and function of large extracellular vesicles (LEVs), particularly in the modulation of the bony microenvironment in advanced prostate cancer through its specific interaction with caveolin-1 which is implicated in the genesis of hormone refractory and metastatic prostate cancer.
| MATERIALS AND METHODS

| Cell culture
The human prostate cancer cell lines used in this study are LNCaP, C4, C4-2, and C4-2B. Of these, the LNCaP cell line (as its fast growing version, FGC) was originally purchased from American Type Culture Collection (ATCC, Manassas, VA). The sublines C4, C4-2, and C4-2B
derived from the parental LNCaP were originally developed and extensively characterized by Chung and his laboratory. 12, 13 These cell lines were procured originally from ViroMed, Inc., Atlanta, GA and preserved in liquid nitrogen and cultured as described previously.
21,22
The non-cancerous immortalized human prostate epithelial cell line RWPE-1 was purchased from ATCC and cultured in a medium containing keratinocyte serum free medium supplemented with bovine pituitary extract and human recombinant epidermal growth factor (Invitrogen, Inc., Waltham, MA).
| Antibodies and reagents
Antibodies to NQO2 (monoclonal) was purchased from Origene 2.5 | Semi-quantitative PCR amplification of NQO1, NQO2, and β-actin transcripts
The design of the sense and anti-sense primers for the genes NQO1, NQO2, and β-actin (for expression control) was done exactly as described previously by Strassburg et al. 27 NQO1, NQO2, and β-actin genes were amplified separately using the specific primers, under the PCR conditions described by these authors, using the thermostable TaqMan DNA polymerase (Applied Biosystems, Inc., Foster City, CA) and Applied Biosystems Gene Amp PCR system 2400. One tenth of the total PCR product for each was run on a 1% agarose gel containing 1 µg/mL ethidium bromide and the gel was imaged through the gel documentation system. Under these conditions, NQO2, NQO1, and β-actin yielded a PCR product of 623, 366, and 202 bps, respectively. All cell proliferation assays were done in duplicate. | 1183 used as the detergent resistant fraction. Both fractions were centrifuged at 15 000g for 30 min and the supernatants were used for analysis.
| Double immunofluorescence for probing caveolin-1 and NQO2
The four prostate cancer cell lines were cultured on Lab Tek II 4-well chamber slides as mentioned before. When they were 70% confluent, and sealed with a cover slip. The immunofluorescence of the two fluorochromes were captured using the Nikon fluorescence microscope as described earlier.
| GST-caveolin-1 (wt and deletion mutants) pull down assay
The full length caveolin-1 (cav-1, amino acids 1-178) and its deletion The bound proteins were eluted and denatured with 2X SDS-PAGE denaturing buffer and subjected to gel electrophoresis under denaturing conditions. The resolved proteins were transferred to PVDF membranes as described above and probed with anti-NQO2
antibody (monoclonal, Origene Technologies, Inc.).
| Isolation of large extracellular vesicles (LEVs)
LEVs were purified by differential centrifugation from the condi- 3 | RESULTS
| Differential expression of NQO2 in the prostate cancer progression model system
The relative levels of expression of the enzyme NQO2 and caveolin-1 were followed using the whole cell extracts of LNCaP, C4, C4-2, and C4-2B cells. As negative and loading controls, the expression levels of the enzyme NQO1 as well as β-actin were also followed on the same gels by re-probing the blots. The results are shown in Figure 1A . It is evident that while caveolin-1 expression progressively increased, the level of NQO2 changed in a biphasic manner, first increasing from LNCaP to C4, peaking at C4-2 followed by a precipitous decrease at the C4-2B stage. These results, at the minimum, suggest that NQO2 is being unexpectedly reduced compared to caveolin-1 in C4-2B cells. To obtain additional information on the discordant changes in NQO2 and caveolin-1 with respect to prostate cancer progression and metastasis, total RNA was prepared from these cells and mRNA expression corresponding to NQO1, NQO2, and β-actin was assayed by RT-PCR. In contrast to the immunoblots data shown in Figure 1A , relatively constant levels of mRNA expressions of FIGURE 1 A, Relative levels of expression of NQO2, NQO1, caveolin-1, and β-actin in the LNCaP prostate cancer progression model system. Characteristically, the level of expression of NQO2 is decreased in C4-2B cells when the whole cell extracts were analyzed. Whereas, the expression levels of caveolin-1 showed a progressive increase in this model system. This apparent inverse relationship between these two proteins formed the basis of our further investigations. As a negative control, the expression levels of a related oxidoreductase NQO1 showed no changes in this progression model system. B, RNA expression pattern for NQO2, NQO1, and β-actin in the LNCaP prostate cancer progression model system. The specific primers designed generated a band of 623 bp (base pairs) for NQO2; 366 bp for NQO1 and 202 bp for β-actin. See section 2 for the design of the primers and experimental details. C, Oxidative stress analysis in the LNCaP prostate cancer progression model system, using the CellROX oxidative stress analysis kit. between amino acids 100 and 107 of NQO1 also conforms to the consensus CBD. However, the sequences in NQO2 (149-157) and in NQO1 (100-107) are buried in the core of the protein, near the isoalloxazine ring of the flavin binding site and hence, not likely to be available for binding to caveolin-1. By contrast, the sequence in NQO2
(175-182) is located at the periphery and spatially available for potential protein-protein interactions with caveolin-1 ( Figure 2C ).
| Glutathione-S-transferase (GST)-fused caveolin-1 construct pull-down assays confirm that NQO2 interacts with caveolin-1
To investigate whether caveolin-1 is a binding partner for NQO2, we performed pull-down assays using a series of caveolin-1 deletion constructs fused with GST and non-denaturing whole cell lysates from LNCaP prostate cancer cells. (>10 μM in diameter) appear to be specific to cancer cells. [33] [34] [35] In particular, prostate cancer cells are known to typically release LEVs which allow them to carry critically significant signaling proteins and other cargo such as microRNAs, etc. across tissue barriers. 36 Recent work of Di Vizio et al 37 showed that the LEV release from prostate cancer cells into the blood appear to correlate with advanced metastatic disease and caveolin-1 was identified as the serum LEV biomarker. Therefore, these observations prompted us to explore the possibility of the release of these LEVs in the well characterized prostate cancer progression model system of LNCaP and C4-2B. Since it is already known that caveolin-1 is an integral component of these LEVs, we hypothesized that NQO2 could also be a cargo carried by these LEVs to modulate the oxidative stress of the neighboring cells.
Our studies indicate that the release of LEVs is greatly increased in the C4-2B cells as opposed to the parental LNCaP cells and that the extrusion of both caveolin-1 and NQO2 could be visualized in the LEVs as shown by double immunofluorescence studies ( Figure 4A ). As a negative control, we also looked for the disposition of the related oxidoreductase NQO1 and found that it was not released in the LEVs from C4-2B cells ( Figure 4B ).
3.7 | The C4-2B cells are glutamine addicted as compared to LNCaP, C4, and C4-2
We performed cell proliferation studies in rich as well as glutamine deficient medium after seeding a constant number of cells in 6-well plates. Compared to LNCaP, C4, and C4-2 cells, C4-2B showed a 60% reduction in proliferation when grown in glutamine deficient medium.
Similar results were obtained when C4-2B cells were grown in rich medium in the presence of 10 μM BPTES, the specific inhibitor of GLS (figure not shown). Our results suggest that these C4-2B cells are critically dependent on the presence of glutamine for their metabolism, survival, and proliferation, compared to its parental derivatives.
| The formation and extrusion of LEVs from C4-2B cells are critically dependent upon glutamine metabolism, particularly glutaminase (GLS) activity
Interestingly, we also found that the release of these LEVs is critically dependent upon the presence of glutamine and its metabolism, particularly the pathway mediated by the kidney type GLS. Figure 5A shows a significant reduction in LEV production from the highly bone metastatic C4-2B cells when the enzyme GLS was specifically inhibited by the compound BPTES. For this study, the double immunofluorescence of both NQO2 and caveolin-1 were followed, as described for Figure 4A . Further supporting our observation, studies from other laboratories indicate that proteins enriched and exported in LEVs included enzymes involved in glucose and glutamine metabolism. Recent results of Minciacchi et al 38 show that the glutamine metabolism was altered in cancer cells exposed to LEVs. These authors showed in their DU-145 metastatic prostate cancer system, the GLS enzyme was highly and uniquely expressed in the LEV cargo fraction. This prompted us to investigate whether GLS enzyme was also present in the LEVs identified in the C4-2B bone metastatic system. Figure 5B shows that the GLS extrusion in the LEVs budding from C4-2B cells (which is not seen in the parental LNCaP, C4, and C4-2 cells, figure not shown) as visualized by
immunofluorescence. This GLS extrusion in the LEVs from C4-2B cells could be completely inhibited by BPTES as seen in Figure 5B .
| Parallel immunoblot analyses confirm the immunofluorescence pattern of C4-2B cells
To gain further supporting evidence for the presence of NQO2, caveolin-1, and GLS in these LEVs, we also performed immunoblot analyses on the isolated LEVs from different stages of prostate cancer, as exemplified by the LNCaP progression model system. Figure 6A shows the results of immunoblots when the whole cell lysates (WCE) and the LEVs fractions were run on the same blot and probed with the respective antibodies such as NQO1, RhoC, β-actin, and GLS. Of these, the first two proteins served as negative controls. NQO1 is only seen in the WCE fraction and not in the LEV fraction, a pattern also seen in the immunofluorescence studies ( Figure 4B ). The RhoC protein is exclusively cytoplasmic and hence not seen in the LEV fraction. A small pool of β-actin protein could be seen in the LEV fraction which is an indication that the LEV blebbing and release in the C4-2B system is critically dependent on the cytoskeletal organization just below the plasma membrane and that a fraction of the actin filament proteins such as β-actin is also extruded in these LEVs. This phenomenon is not seen when parallel studies were done on exosomes as opposed to LEVs (data not shown). β-actin shedding in LEVs could also be seen in the breast cancer system as reported independently by another study. 39 Thus, β-actin shedding in several cancer systems appears to be specific to LEVs. Coincidentally, the extrusion of β-actin could be inhibited to a large extent by the GLS specific inhibitor BPTES. We also confirmed the presence of the enzyme GLS in these LEVs from C4-2B cells, the extrusion of which is again dependent upon glutamine metabolism, particularly GLS activity, as evidenced by the inhibition of its own shedding by the GLS specific inhibitor BPTES. These observations give a new meaning for the selfserving nature of glutamine addiction in cancers. In Figure 6B , we further 
| The osteomimicry of the C4-2B prostate cancer cells is dependent upon glutamine metabolism
Finally, since we had characterized the link between glutamine metabolism and the extrusion of LEVs in the highly bone metastatic C4-2B prostate cancer cell line, we wished to find out whether the FIGURE 4 A, Release of LEVs from C4-2B cells. LNCaP, C4, C4-2, and C4-2B cells were grown on four well chamber slides, semi-confluent cells were then fixed in methanol:acetic acid mixture and processed for double immunofluorescence after blocking the slides with 5% normal donkey serum in 1XPBS and 0.5% TritonX-100. A Caveolin-1 rabbit polyclonal antibody (Santa Cruz Biotechnologies, Inc.) and a monoclonal antibody against NQO2 (Origene Technologies, Inc.) were used, each at 1:150 dilution. Invitrogen's AlexaFluor-488 conjugated to donkey anti-rabbit IgG was used to bind to the caveolin-1 primary antibody and AlexaFluor-594 conjugated to donkey anti-mouse antibody was used to bind the NQO2 primary antibody. Processing and washing and final mounting were done according to manufacturer's protocol (Vector Labs, Inc.). The final mounting medium (Vector Labs, Inc.) also contained the dye DAPI, specific for nuclear staining. The LEVs that are shedding out of C4-2B cancer cells can be seen (white arrows). B, As a negative control to the immunofluorescence studies done for (A), single immunofluorescence studies were done on the same cells grown in chamber slides using a monoclonal antibody for the oxidoreductase NQO1, using a secondary antibody conjugated to AlexaFluor-594, as shown for (A). 
FIGURE 6
A, Immunoblot analysis of biomarker proteins that are packaged in the LEVs that arise from the RWPE-1, LNCaP, C4, C4-2, and C4-2B cells. WCE: Whole cell lysate; LEV, large extracellular vesicles. In (A), expression levels of the oxidoreductase NQO1, the cytoplasmic RhoC, β-actin, and glutaminase (GLS) were followed in the absence (−) and in the presence of 10 µM BPTES. B, The expression levels of the LEV marker Flotillin-1, the enzyme NQO2, and Caveolin-1 were followed both in the absence (−) and in the presence (+) of 10 μM BPTES. C, C4-2B cells show decreased osteomimetic properties when grown in medium supplemented with the glutaminase (GLS) inhibitor BPTES (10 µM). In this immunoblot the expression levels bone sialoprotein (BSP, an osteoblastic marker), RANK (receptor activator for NF-kB, an osteoclastic marker), parathyroid hormone-related protein (PTHrP, an osteoclastic marker) were followed against a backdrop of the expression levels of β-actin as loading control. [Color figure can be viewed at wileyonlinelibrary.com] that these LEVs bypass the extracellular and tissue barriers to fuse with the target non-cancerous cell types (in the stromal compartment) and influence their metabolic and signaling pathways. 62, 63 Our studies are also important from a translational point of view.
For example, there are several reports that suggest a role of a sudden oxidative burst in otherwise silent micrometastases that allow them to "wake up" from tumor dormancy. Based on the studies presented here and considering the fact that NQO2 can produce ROS under special circumstances, it is tempting to speculate that such events may be the "trigger" or a wake-up mechanism for prostate cancer micrometastases, a mechanism which could well be used by other cancers such as breast cancer. 64, 65 Other FIGURE 7 A diagrammatic sketch of the impact of reprogrammed glutamine metabolism in regulating the formation of bone metastases in prostate adenocarcinoma. The duality of the function of NQO2 as a generator of oxidative stress as well as a stabilizer of p53 (in a nonenzymatic fashion) is also depicted. The balance between these two processes, along with the extent to which the tumor is addicted to glutamine and the level of fatty acid synthase (FASN) activity may ultimately determine the cancer cell's propensity to establish organ-specific metastasis. Several other strategies are available to modulate glutaminase activity, such as the use of organo-selenium compounds. All these factors may promote the formation of an organ specific (in this case bone metastatic) niche. As described in the text, the balance of these processes may also help determine the extent of tumor dormancy. Further studies are needed to examine all the hypotheses proposed. Further studies are needed to explore these interesting possibilities.
Our results give a molecular explanation for the significance of overexpression of caveolin-1 and its externalization with regards to how it may influence hormone refractoriness and bone metastasis in a metastatic progression model system. This behavior is greatly aided by an enhanced dependence on glutamine metabolism, which facilitates enhanced lipid synthesis (needed for the formation of LEVs) through GLS, glutamate dehydrogenase(GDH), reductive carboxylation of α-ketoglutarate (α-KG) through isocitrate dehydrogenase (IDH), citrate lyase and finally FASN as shown in Figure 7 .
This paradigm integrates the role of enhanced glutamine metabolism, enhanced lipid synthesis and lipid metabolism in the establishment of organ specific metastases. [75] [76] [77] [78] Finally, our results suggest a glutamine/GLS-mediated metabolic reprogramming in the LNCaP model system as it progresses toward C4-2B is an integral component of the force driving the metastatic process. Based on the results of our studies, a combinatorial strategy using anti-metastatic therapies such as NBPs and anti-GLS therapy, or alternatively, a cocktail consisting of naturally occurring plant compound based anti-NQO2, anti-GLS, and anti-FASN drugs could be considered for treating advanced prostate cancer patients with bone metastatic complications. We would like to suggest that the release of caveolin-1, GLS, NQO2, etc, in these LEVs could make them an ideal diagnostic and prognostic marker (in the serum) for advanced prostate cancer patients. LEVs in these cancer systems are known to pack a multitude of other oncogenic proteins, regulatory microRNAs, etc. Thus, the extrusion of a specific protein such as GLS or NQO2 may be indicative of the severity of the disease.
